GlassScriptPhysician profile
Bhuvnesh Aggarwal
NPI 1760770101
$17,699.68
in general payments reported to CMS, 2019-2025
25 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $200 · 2021: $771 · 2022: $8,725 · 2023: $4,338 · 2024: $2,759 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,864 · Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,863.97 |
| Food and Beverage | $2,769.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,227.23 | 2022-2025 | Corevalve Evolut R, Linq II |
| Edwards Lifesciences Corporation | $1,960.73 | 2019-2022 | |
| Boston Scientific Corporation | $1,913.94 | 2022-2024 | Watchman Access System |
| Abbott Laboratories | $1,899.22 | 2019-2024 | Amplatzer Amulet, Cardiomems, Amplatzer Talisman |
| Philips North America LLC | $629.05 | 2024 | (9525) Intracardiac Und |
| Amgen INC. | $566.30 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $272.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $263.63 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.85 | 2019-2021 | |
| Abiomed | $131.45 | 2024 | Impella |
| Pfizer INC. | $109.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.56 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $63.70 | 2019-2024 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $61.15 | 2021-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.79 | 2022-2023 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $44.91 | 2024 | |
| Amarin Pharma, INC. | $43.36 | 2020-2021 | |
| Novo Nordisk INC | $35.59 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $25.50 | 2025 | |
| Mannkind Corporation | $25.50 | 2025 | |
| Recor Medical INC | $25.44 | 2025 | Paradise Ultrasound Renal Denervation System |
| Irhythm Technologies, INC. | $24.65 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.31 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $22.32 | 2022 | |
| Medtronic Vascular, INC. | $17.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhuvnesh Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.